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The extended one-generation reproduction toxicity study (EOGRTS; OECD test guideline 433) is a new
and technically complex design to evaluate the putative effects of chemicals on fertility and develop-
ment, including effects upon the developing nervous and immune systems. In addition to offering a more
comprehensive assessment of developmental toxicity, the EOGRTS offers important improvements in
animal welfare through reduction and reﬁnement in a modular study design. The challenge to the
practitioner is to know how the modular aspects of the study should be triggered on the basis of prior
knowledge of a particular chemical, or on earlier ﬁndings in the EOGRTS itself, requirements of speciﬁc
regulatory frameworks notwithstanding. The purpose of this document is to offer guidance on science-
based triggers for these extended evaluations.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The reproductive cycle in eutherian mammals is a complex,
highly-integrated process that may be adversely affected by toxi-
cant acting at different stages of the cycle and through diverse
modes of action. While various study designs have been developed
to assess the potential effects of chemicals and agrochemicals upony Assessment; DIT, develop-
toxicity; ECETOC, European
als; EOGRTS, extended one-
limpet haemocyanin; OECD,
ent; PND, postnatal day; (Q)
R, T-cell dependant antibody
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Inc. This is an open access article uselected parts of the reproductive cycle (ECETOC, 2002), the two-
generation reproductive toxicity testdOECD Test Guideline 416
(OECD, 2001a)dhas been considered the ‘gold standard’ for the
holistic assessment of effects on reproduction as exposure to a test
substance is maintained throughout the cycle.
The two-generation reproductive toxicity test is usually carried
out in the rat as the preferred species. Groups of animals are
exposed to the test substance for ten weeks prior to mating,
throughout the mating period, gestation, and lactation through to
weaning, at which point selected individuals of the F1 generation
are maintained on the same exposure protocol to produce the F2
generation (Fig. 1A). The study design is animal-intensive, with
approximately 2600 animals being used throughout the course of a
standard study (Cooper et al., 2006), and allows evaluation of ef-
fects on mating behaviour; fertility; in utero and postnatal devel-
opment, including landmarks of sexual development and
maturation; and reproductive tract organs. The test does not,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic diagrams of (A) the two-generation reproductive toxicity study, OECD TG 416, and (B) the extended one-generation reproductive toxicity study, OECD TG
443. (A) Animals are 5e9 weeks of age at the start of treatment. Treatment of males and females continues for ten weeks prior to pairing; during the pairing period, up to two
weeks’ duration; and females are then continuously treated during gestation and lactation to three weeks postpartum when the offspring are weaned and the dams are sacriﬁced.
Parental males are sacriﬁced when no longer needed for assessment of reproduction, usually shortly after parturition when postnatal survival of the offspring is assured. Litter sizes
may be standardised at PND 4, and at weaning are reduced to one male and one female, which go on to produce the second generation. (B) Animals are usually treated for two
weeks prior to pairing, although this may be extended if additional information or regulatory requirements necessitate; throughout the pairing period; females are then
continuously treated during gestation and lactation to three weeks postpartum, when the offspring are weaned and the dams are sacriﬁced; parental males are continuously treated
for a minimum of ten weeks. Litter sizes may be standardised at PND 4, and at weaning the offspring are allocated randomly to the cohorts; one male and one female from each
litter are assigned to cohorts 1A and 1B, one male or one female is assigned to each of cohorts 2A, 2B, and 3. If the second generation (F2) mating is not required, cohort 1B animals
are necropsied at approximately 14 weeks of age. If the second generation mating is required then, based on weight of evidence, it may be sufﬁcient to terminate all cohort 1B
progeny (F2 litters) on PND 4. Shaded bars, direct exposure to the test substance; open bars, indirect exposure, although for substances administered in the diet or drinking water
offspring do become directly exposed from around the end of the second week postpartum; black bars, necropsy; black triangles, interim litter standardisation at PND 4 (optional)
and weaning. P0, ﬁrst generation parental animals; F1, ﬁrst generation offspring; P1, second generation parental animals; F2, second generation offspring.
N.P. Moore et al. / Regulatory Toxicology and Pharmacology 80 (2016) 32e40 33however, evaluate effects on all facets of the reproductive cycle,
such as the developing nervous and immune systems. Furthermore,
recent analyses have questioned the practical and scientiﬁc value of
mating the F1 generation to produce the F2 generation at a sub-
stantial cost in terms of animal use (Janer et al., 2007; Piersma et al.,
2011; Rorije et al., 2011).
An alternative study designdthe extended one-generation
reproduction toxicity study (EOGRTS)dwas originally proposed
by the ILSI Health and Environmental Sciences Institute’s Agricul-
tural Chemical Safety Assessment (ACSA) Technical Committee, as
part of a tiered testing approach for agricultural chemicals (Cooper
et al., 2006). This test design incorporated the preliminary assess-
ment of developmental neurotoxicity (DNT) and developmental
immunotoxicity (DIT) and removed the mandatory requirement for
a second generation breeding. At that time the logic for including
DNT and DIT assessments in a one generation study was that for
agricultural chemicals DNT was a quasi-mandatory testing
requirement, and requests to investigate immune toxicity
(including DIT) started to increase. The inclusion of DNT and DIT
assessments into the EOGRTS was considered to be a more efﬁcient
way to address these testing requirements.
An essential difference between the EOGRTS and the two-
generation reproduction toxicity study is the omission of the sec-
ond breeding. In support of the proposal to remove the second
breeding as a standard requirement ACSA cited an unpublished US
EPA review of data collected on the F2 generation from studies of
350 pesticides which indicated that, in all except two possible
cases, adverse effects would have been identiﬁed in the ﬁrstgeneration or from other toxicity studies (Cooper et al., 2006).
Additional evaluations of the added value of the F2 generation
breeding have since examined its impact upon hazard identiﬁca-
tion (classiﬁcation) and risk assessment (identiﬁcation of NOAEL
and LOAEL values), as well as the sensitivity of internal triggers
from the F1 generation (Dang et al., 2009; Janer et al., 2007; Myers
et al., 2008; Piersma et al., 2011; Rorije et al., 2011). An analysis of
two-generation studies for ﬁfty substances that are classiﬁed for
effects on reproduction revealed that in only one case was the
classiﬁcation determined by unique effects in the second breeding
phase, but that in this case further testing would have been trig-
gered by other available data (Rorije et al., 2011). Furthermore, in a
key analysis of 498 two-generation studies representing 438 sub-
stances the second breeding did not drive the derivation of the
NOAEL (Piersma et al., 2011).
Based on data suggesting that the second breeding adds little or
no critical information to hazard and risk assessment, ACSA pro-
posed that examination of second generation was unnecessary
unless triggered by adverse effects in the parental animals or F1
progeny (Cooper et al., 2006). Eventually a fully modular study
design was proposed in which the DNT and DIT as well as other
evaluations would also be triggered if data from studies in parent
animals, the F1 generation, or other toxicological investigations
suggested a potential for adverse effects on neurodevelopment or
the immune system. If there were no alerts from appropriately
designed and robust studies, then such evaluations could bewaived
rather than being a mandatory requirement (ECETOC, 2008a,
2008b; Moore et al., 2009; Vogel et al., 2010). The OECD adapted
1 Where speciﬁc OECD Test Guidelines are noted, equivalent regulatory test
guidelines also apply.
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ﬂexibility and emphasise the importance of existing knowledge in
study design (OECD, 2011a). The OECD test guideline (TG) describes
three cohorts of F1 generation animals that may be used to address
speciﬁc developmental endpoints (Fig. 1B). The conduct of these
cohort evaluations are not mandatory to the validity of the test, nor
are they default requirements in all regulatory frameworks, such as
REACH (EU, 2007, 2015). Thus OECD TG 443 offers ﬂexibility in the
conduct of these evaluations:
“Decisions on whether to assess the second generation and to
omit the developmental neurotoxicity cohort and/or develop-
mental immunotoxicity cohort should reﬂect existing knowl-
edge for the chemical being evaluated, as well as the needs of
various regulatory authorities.” (OECD, 2011a)
In order to reduce the number of animals and procedures
involved in meeting the requirements of speciﬁc regulatory
frameworks, a set of triggers and waivers for the inclusion or
exclusion of evaluations was proposed that allow the EOGRTS to not
only reduce animal use, but to reﬁne their use in terms of limiting
unnecessary manipulations (ECETOC, 2008a, 2008b; Moore et al.,
2009). Indeed, the core study design provides sufﬁcient evidence
to inform hazard identiﬁcation for reproductive, DIT, or DNT effects
in the progeny where prior knowledge for effects is unavailable.
The purpose of this communication is to give further practical
guidance on the identiﬁcation and exercise of triggers and waivers,
in order to optimise the reduction and reﬁnement possibilities that
the OECD TG 443 presents but without compromising hazard
identiﬁcation and risk assessment. It is important to note that there
are different technical standards for developing a waiver compared
to a trigger. A trigger is, generally, a clear indication that further
testing is needed, whereas a waiver is a compilation of evidence
that no further testing is necessary, therefore the data that are
required for a waiver generally need to be more robust.
2. Overview of the EOGRTS test guideline
The test is designed to evaluate the effects of chemicals on pre-
and postnatal development; the integrity of the male and female
reproductive systems; and systemic toxicity in males, pregnant and
lactating females, and young and adult offspring (OECD, 2011a). An
overview of the test design is represented schematically in Fig. 1B.
The test substance is administered to groups of sexually-mature
male and female animals for a minimum of two weeks prior to
mating, although up to ten weeks may be preferred under some
regulatory frameworks; during the mating period, of maximum
two weeks’ duration; and throughout gestation and lactation until
weaning of the offspring (females); or at least until weaning of the
F1 offspring, and for a minimum of ten weeks (males). Selected
offspring are further administered the test substance until the time
of scheduled necropsy. Litter size may be adjusted at postnatal day
(PND) 4, and again at weaning once F1 animals have been assigned
to their respective cohorts.
Clinical observations and pathology examinations are under-
taken on all animals to evaluate signs of toxicity, with particular
emphasis on the integrity of the male and female reproductive
systems, and the growth, development, and function of the
offspring. At weaning, offspring may be assigned to cohorts to
further evaluate the effect of the test substance upon speciﬁc
developmental and reproductive endpoints.
2.1. Cohorts
Litter size may be adjusted according to the normal litter size ofthe strain being used, so that there are eight to ten F1 offspring at
the time of weaning (OECD, 2011a, 2013). They are assigned to
cohorts in order to examine the effects of the test substance upon
speciﬁc aspects of development: cohort 1, reproduction; cohort 2,
DNT; cohort 3, DIT:
 Cohort 1A. One male and one female from each litter are
assigned to evaluate effects upon the reproductive system and
general systemic toxicity.
 Cohort 1B. One male and one female from each litter are
assigned to evaluate reproduction and fertility of the F1 gener-
ation, if triggered, or otherwise to conﬁrm equivocal effects
upon the reproductive system in cohort 1A.
 Cohort 2A. One male or one female from each litter is assigned
for neurobehavioral testing and subsequent neuro-
histopathology assessment as adults.
 Cohort 2B. One male or one female from each litter is assigned
for neurohistopathology assessment at weaning.
 Cohort 3. One male or one female from each litter is assigned to
evaluate T-cell dependant antibody response at eight weeks of
age.
 Surplus. Remaining unselected pups are subjected to gross pa-
thology examination and used for T4 and TSH on PND 22.
All F1 animals from cohorts 1, 2A, and 3 are evaluated for age at
which sexual maturation is attained and for external abnormalities
of the reproductive tract organs.
3. Use of available data in planning the EOGRTS
The EOGRTS is a resource-intensive and complex study, and it
will not be performed in the absence of data that at least allow
adequate dose selection (OECD, 2011a). Attention herein is given to
information that is routinely available within the tiered and inte-
grated testing strategies that are required under the standard
regulatory frameworks for industrial and agricultural chemicals. As
advances are made in alternative screening methods, additional
tests may become a routine part of the standard testing strategies,
thereby providing additional information to the decision-making
process.
This guidance begins with the assumption that the EOGRTS will
generally be performed without the modules for DNT (cohort 2)
and DIT (cohort 3), and that a breeding to produce a second gen-
eration (cohort 1B) in not necessary. Prior to the conduct of the
EOGRTS, relevant data for the identiﬁcation of triggers could be
available from one or more of the following sources1:
 In the absence of any directly relevant data for the substance
under consideration, structure-activity relationships or refer-
ence to class chemicals for which relevant data are available
may be useful. Given the complexity of the EOGRTS some data
for the substance will likely be available, from dose range-
ﬁnding tests, for example; but data for speciﬁc triggers may
not. Note that lack of identiﬁed SAR concerns should not be
construed as a waiver.
 Acute toxicity data in rodents (OECD, 2001b, 2001c, 2008a).
Acute toxicity tests may be of some use with respect to the
presence of effects upon the nervous system. Compared to
repeated-dose toxicity study designs exposures or doses in
acute tests are high; are administered once; and oral doses are
given by gavage resulting in high peak plasma concentrations.
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life clinical observations and gross pathology. Data from
repeated-dose toxicity studies may be more relevant.
 Repeated dose toxicity in rodents (OECD, 1998, 2008b, 2009a,
2015a). In-life observations during the conduct of 28-day and
90-day repeated dose toxicity studies may reveal potential ef-
fects upon the central and peripheral nervous systems, endo-
crine system, and immune system.
 Reproductive/developmental toxicity screening studies or
endocrine disrupter screening studies in rodents (OECD, 1995,
1996, 2007a, 2009b, 2015a, 2015b). In addition to signs of
adverse reaction to treatment relevant to the selection of doses
for the conduct of the EOGRTS (OECD, 2011a), screening studies
may provide initial or supporting evidence for adverse effects
upon fertility or development that could require further evalu-
ation, or supporting evidence for equivocal ﬁndings in cohort
1A. These study designs are, however, limited in terms of sta-
tistical power and/or mechanistic scope when compared to the
EOGRTS; negative ﬁndings on their own should not be
construed as conclusive evidence of no concern and thus a
waiver against further evaluation.
 Prenatal developmental toxicity (OECD, 2001d). The prenatal
developmental toxicity study design examines a speciﬁc subset
of the reproductive cycle, and may foretell the manifestation of
morphological or functional deﬁcits during postnatal
development.4. Technical triggers and waivers for the speciﬁc cohorts
Triggers fall into one of two broad categories: the identiﬁcation
of effects that predict potential or concern for toxicity in the
offspring; and effects in adults that raise concerns for the devel-
oping offspring as a sensitive subpopulation. Cohort 1A is integral
to the EOGRTS, and the application of triggers applies only to the
mating of F1 animals in cohort 1B to produce a second generation.
Given the resource intensiveness and logistical complexity of the
EOGRTS, triggers for cohorts 2 and 3 are only envisaged from prior
information that is available during the design phase of the study,
and not from observations made during the conduct of the study
itself (Table 1).
When evaluating endpoints as triggers for a study their strength
of association and speciﬁcity need to be considered. Strength of as-
sociation indicates conﬁdence in a true causal relationship between
effect and treatment. Effect frequency, magnitude relative to
background, and treatment correlation (including time course and
dose response) are primary contributors to strength of association.
Speciﬁcity is the degree to which an effect is qualitatively related to
treatment with the test item, whether it’s a primary effect of
treatment or arises secondarily to another response. Together they
determine the conﬁdence that the response is a treatment-related
effect of regulatory concern, as opposed to a chance or secondary
response. Effects that are clearly related to treatmentdeither in the
EOGRTS or from previous studiesdmay not require conﬁrmation if
they are sufﬁcient to conclude on hazard identiﬁcation (classiﬁca-
tion) and risk assessment, such effects effectively become waivers;
those that are equivocally related to treatmentdfor example
achieving only borderline statistical signiﬁcance, unclear dose-
relatedness, or minor deviation from historical controldmay
require conﬁrmation.
Reproduction is a highly complex and integrated function, and
sometimes changes in measured endpoints reﬂect non-speciﬁc
responses to stress or biological variability (Moore et al., 2013).
When identifying parameter changes as triggers for further inves-
tigation, care must be taken to ensure that the effect is a directresponse to treatment and is not a secondary or non-speciﬁc
response. Proper statistical analysis is critical when making this
determination, particularly when endpoints are interdependent,
but statistical signiﬁcance should not be the sole determinant.
OECD guidance on the evaluation of repeated-dose and reproduc-
tive toxicity data is available, and following this guidance is
strongly recommended (OECD, 2002a, 2002b, 2008c). The ﬁnal
decision on trigger selection should be made using expert judge-
ment and must be fully justiﬁed in the ﬁnal report.
4.1. Triggers for cohort 1B (breeding to produce the F2 generation)
ACSA proposed that second breeding to be triggered by adverse
effects in the parental animals or F1 progeny, speciﬁcally impaired
fertility or fecundity of the parental generation; abnormal sexual
development of the F1 pups; or postnatal mortality or toxicity to the
F1 pups prior to weaning. The OECD published guidance on triggers
for the second generation breeding to be applied to studies con-
ducted under the Canadian Pest Management Regulatory Agency
and the United States Environmental Protection Agency’s Ofﬁce of
Pesticide Programs. The triggers largely reﬂect those originally
proposed by ACSA (Cooper et al., 2006), speciﬁcally effects on F0
fertility; F1 oestrus cycle; litter size; F1 developmental landmarks;
postnatal mortality; pup malformations; decreased live birth in-
dex; and decreased pup body weight (OECD, 2011b). ACSA had
recognised that, due to the complexity and interrelatedness of the
evaluations, it was likely that any critical or equivocal effect on
reproduction would be detected and would trigger breeding of the
F1 generation (Cooper et al., 2006). Indeed, a review of nine two-
generation reproductive toxicity studies indicated that the trig-
gers proposed by ACSA would have resulted in the second gener-
ation breeding in ﬁve out of six cases in which reproductive effects
were observed (Beekhuijzen et al., 2009).
The application of triggers should be exercised in recognition of
the evidence that the second breeding adds little or no impact to
the overall hazard and risk assessment (Janer et al., 2007; Piersma
et al., 2011; Rorije et al., 2011), and considering the feasibility of
their application under speciﬁc circumstances (Fegert et al., 2012).
Unless dictated by speciﬁc regulatory frameworks the second
breeding should be triggered only to conﬁrm otherwise equivocal
ﬁndings. Effects that are clearly related to treatment should not
require conﬁrmation if they are sufﬁcient to conclude on hazard
identiﬁcation (classiﬁcation) and risk assessment. Likewise, the
absence of any effect on reproduction toxicity would not require
further testing. Thus the unequivocal presence or absence of effects
are effectively waivers for cohort 1B.
With regards to the speciﬁcity of effects, the following consid-
erations should be taken into account:
 The most sensitive endpoints to determine effects upon fertility
in rats are organ weights, sperm parameters, and histopathol-
ogy, rather than litter size (Blazak, 1989; Moore et al., 2013). The
assessment of these endpoints in the F1 generation is a
requirement of the test guideline, so if reduced litter size or
implantations is observed in the presence of signiﬁcant,
biologically-relevant changes in these other endpoints then a
second breeding should not be required because it would not
alter the overall assessment. Since these endpoints are interre-
lated, the assessment should take into account all available data.
The assessment of organ weights should take into account po-
tential inﬂuence of body weight; it may be preferable to apply
analysis of covariance (ANCOVA) rather than express organ
weights relative to body weight (Shirley, 1977).
 Litter size is inﬂuenced by the number of ova released prior to
conception, which is reﬂected by the number of corpora lutea
Table 1
Triggers and waivers for additional cohorts within the EOGRTS. Effects that are clearly related to treatment, and for which decisions on hazard identiﬁcation and risk
assessment can be made, as well as effects that are clearly a secondary response to systemic toxicity may not necessarily result in further investigation. The ﬁnal decision
should be based on the weight of all available evidence.
Cohort Internal triggers (þ) and waivers () External triggers
F0 F1
1B (F2 generation) þ Y Matings þ Y Litter size þ Evidence of an endocrine disrupting mode of action
þ Y Fertility (implantations, pregnancy rate) þ Y Litter/pup weight
þ [ Gestation length þ Anogenital distance
 Y Reproductive organ weights, pathology þ Nipple/areola retention
e Sperm parameters
þ Age at sexual maturation
þ Oestrus cycle
2A & 2B (DNT) None (impractical) None (impractical) þ SAR or chemical class (neurotoxicity)
þ Evidence of mechanistically-relevant endocrine disrupting activity
þ Evidence of a relevant neurotoxic mode of action
þ Functional or morphological neurotoxicity in adults
þ Y Surface righting reﬂex
þ Y Thyroid weight and pathology
3 (DIT) None (impractical) None (impractical) þ SAR or chemical class (immunotoxicity)
þ Evidence of mechanistically-relevant endocrine disrupting activity
þ Altered weight or pathology of lymphoid organs
þ Altered cellularity of bone marrow, spleen, thymus, or lymph nodes
þ Altered differential white cell counts
þ Functional immunotoxicity in adults
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counts have been related to low body weight prior to mating
(Chapin et al., 1993), and thus care should be taken to ensure
that reductions in litter size cannot be attributed as a secondary
response to effects upon maternal weight. It is not feasible to
count corpora lutea in the context of the EOGRTS, but data from
other relevant studies may prove useful.2
 Offspring body weight at birth may be inﬂuenced by maternal
body weight, as a reﬂection of nutritional status; litter size; and
proportion of males in the litter (Carney et al., 2004; Griggio
et al., 1997; OECD, 2008c; Romero et al., 1992). Therefore,
identiﬁcation of a speciﬁc treatment-related effect upon
offspring weight should also consider these factors, preferably
using an ad hoc method, such as ANCOVA.
 Anogenital distance is a marker not only of sexual differentia-
tion but also of general growth, and therefore it should be
analysed by ANCOVA using pup body weight as covariate;
otherwise it should be normalised to the cube root of pup body
weight (Gallavan et al., 1999).
 A delay or acceleration in the age at which sexual maturation is
attained (opening of the vagina, separation of the prepuce from
the glans penis) may trigger concern. Again, these landmarks
are inﬂuenced by overall growth of the animal, and weight at
attainment should be taken into consideration (Melching-
Kollmuß et al., 2014).
 When considering endocrine activity data, greater weight
should be given to the results of relevant apical studies in vivo,
which more accurately reﬂect the dynamic situation of the
EOGRTS, rather than mechanistic or screening studies in vitro,
which do not take into account the dynamics associated with
toxicokinetics and the interrelatedness of the reproductive
cycle.2 Note that while corpora lutea counts are undertaken in the prenatal develop-
mental toxicity study (OECD, 2001d), treatment is usually initiated some days after
ovulation. Furthermore, while earlier versions of the reproductive toxicity
screening studies allowed assessment of corpora lutea under meaningful treatment
conditions (OECD, 1995, 1996), the current test guidelines do not (2015a, 2015b).
Useful information may, however, be derived from reproductive toxicity screening
studies conforming to earlier guidelines (OECD, 1995, 1996). Malformations in the F1 generation should not be a trigger for
the 1B cohort. Conﬁrmation of malformations is better achieved
through the conduct of a prenatal developmental toxicity study.
If a prenatal developmental study is already available, the
ﬁndings should be considered in toto and a decision then made
as to whether further conﬁrmation through a second breeding
would be meaningful.4.2. Triggers for cohort 2 (developmental neurotoxicity)
Triggers for the conduct of a stand-alone DNT test, such as OECD
TG 426 (OECD, 2007b), have been applied to testing of agricultural
chemicals. A workshop held to discuss triggers, among other as-
pects of DNT testing under the US Environmental Protection
Agency, outlined several that might arise from available data on a
compound, along with levels of concern based on biological effect
(Levine and Butcher, 1990). The biologically-related triggers were
substances that were CNS or behavioural teratogens; adult neuro-
pathic and neuroactive toxicants; hormonally active compounds;
and selective developmental toxicants without CNS effects. The last
of these is less relevant as a trigger for a DNT module within the
EOGRTS because such substancesmay be identiﬁedwithin cohort 1,
and are better characterised by an appropriately designed prenatal
developmental toxicity study.
In repeated dose studies, particularly those required for regu-
latory purposes and conducted according to OECD guidelines,
general clinical examinations are performed on a daily basis as well
as weekly detailed clinical examinations. Examination of clinical
signs include potential occurrence of secretions and excretions and
autonomic activity (e.g. lacrimation, piloerection, pupil size, un-
usual respiratory pattern). Detailed clinical observations should be
performed in an open arena to optimise the detection of anomalies
at the time of the evaluation. Changes in gait, posture, and response
to handling as well as the presence of clonic or tonic movements,
stereotypies (e.g. excessive grooming, repetitive circling), or bizarre
behaviour (e.g. self-mutilation, walking backwards) are also
recorded. In addition, sensory reactivity to stimuli of different types
(e.g. auditory, visual and proprioceptive stimuli), assessment of grip
strength and motor activity assessment should be conducted; a
pre-test observation battery is recommended to establish the
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including cerebrum, cerebellum and medulla/pons), spinal cord (at
three levels: cervical, mid-thoracic and lumbar), peripheral nerve
(sciatic or tibial) preferably in close proximity to the muscle is also
performed. Changes in these parameters could reﬂect neurotoxicity
affecting the central as well as peripheral nervous system and may
form the basis to trigger the conduct of cohort 2. In addition,
knowledge of the mode of action of the chemical (e.g. cholines-
terase inhibition, interaction with receptors involved in neuro-
transmission) should be used as supporting evidence.
Oestrogens play a role in CNS development (Ferguson et al.,
2000), and neurotoxicity has been expressed by neuroendocrine
disrupters in vivo (Waye and Trudeau, 2011). ‘Neuroendocrine
disrupters’ are broadly deﬁned as substances that interferewith the
metabolism or action of “neuropeptides, neurotransmitters, or
neurohormones” (Waye and Trudeau, 2011). Of these, probably
only the last, and possibly the ﬁrst, fall into the more broadly
accepted concept of ‘endocrine disrupter’. Nevertheless, evidence
of endocrine disrupting activity in these systems might be a cause
for further evaluation.
With regards to the speciﬁcity of effects, surface righting reﬂex
is a measure of development and coordination of the vestibular and
neuromuscular systems. Delayed acquisition of the reﬂex may
reﬂect delays in motor development or function, but can also be
affected by general growth of the offspring. Consequently, care
should be exercised not only to take into account the litter as the
unit of analysis, but also those factors that inﬂuence offspring body
weight described abovedbodyweight, litter size, and proportion of
males in the litterdshould be considered as possible covariates.
4.3. Triggers for cohort 3 (developmental immunotoxicity)
The issues of children’s susceptibility to immunotoxicants and
DIT testing have been the subject of much recent signiﬁcant
research, reviews, and workshop discussions (e.g. workshops re-
ported by Boverhof et al., 2014; Holsapple and O’Lone, 2012;
Holsapple et al., 2005; Piersma et al., 2012). Of most signiﬁcance
for the determination of triggers for DIT is the apparent greater
sensitivity of the developing immune system compared to the
mature system present in adults and the relative sensitivity of
functional parameters compared to necropsy ﬁndings (Luebke
et al., 2006; Smialowicz et al., 1988; Tonk et al., 2010, 2011a,
2011b, 2012, 2013a, 2013b; WHO, 2012).
Some assessment of the ‘steady state’ immune system compe-
tence following exposure to a test substance is undertaken as a core
part of the EOGRTS. Splenic cellularity and haematology are eval-
uated in cohort 1A; the spleen and thymus from all F1 adults are
weighed; and spleen, thymus, and samples of bonemarrow from all
F1 adults are preserved for possible histopathology. But these do
not represent a functional response to antigen exposure. Functional
response, which integrates several aspects of the immune system,
is determined in cohort 3 with a T-cell dependant antibody
response (TDAR) assay. As implemented in cohort 3, the TDAR assay
measures the primary antibody response, and is useful in detecting
chemicals that suppress adaptive immunity. In the EOGRTS, a TDAR
assay is undertaken in cohort 3 around postnatal day 56 (OECD,
2011a).
The developing immune system is recognised as more sensitive
to toxic insult than that of the adult (Luebke et al., 2006;
Smialowicz et al., 1988; Tonk et al., 2012), although the evalua-
tions of relative sensitivity have largely deviated from the TDAR
assessment in OECD TG 443dparticularly with reference to the age
at challenge and the parameters that were assessed. Therefore,
their application to the concept of identifying triggers within the
requirements of the test guideline is weakened. Luebke et al. (2006)reviewed the immunotoxicity data for ﬁve sub-
stancesddiethylstilboestrol; diazepam; lead; 2,3,7,8-
tetrachlorodibenzo-p-dioxin; and tributyltin oxideddemonstrat-
ing that the developing immune system was more sensitive in
terms of the doses that elicited an adverse response or persistence
of response; although in most cases the comparison was compli-
cated by differences in dose selection, endpoints reported, species,
or strain. In the case of tributyltin oxide, however, the range of
effective doses in immature and mature animals was similar, and
thymus atrophy was one of the most sensitive endpoints, although
effects were more persistent in immature animals (Luebke et al.,
2006). The lymphocyte proliferation response to T- and B-cell mi-
togens was depressed and persisted to a greater extent in male
Fischer 344 rats that were administered dioctyltin dichloride as
neonates compared to adults. Thymus weight was depressed to a
similar extent in both age groups at the earliest evaluation time
points following cessation of exposure, but was unaffected at later
time points when the lymphocyte proliferation response was still
depressed, and NK cell activity was unaffected (Smialowicz et al.,
1988). Juvenile rats also appeared more sensitive to immunotox-
icity induced by di-(2-ethylhexyl) phthalate in terms of changes in
white blood cell counts, and keyhole limpet haemocyanin (KLH)-
stimulated lymphocyte proliferation and cytokine response ex vivo,
but therewas no difference between the age groups in IgG response
and no change in IgM (Tonk et al., 2012).
Tonk and co-workers have evaluated the relative sensitivity of
several measures of immune status following exposure of juvenile
rats to di-(2-ethylhexyl) phthalate (Tonk et al., 2012); dioctyltin
dichloride (Tonk et al., 2011a, 2011b); ethanol (Tonk et al., 2013a,
2013b); 4-methyl anisole (Tonk et al., 2015); and methyl mercury
(Tonk et al., 2010). Immune status was variously assessed byweight
of lymphoid organs; haematology; spleen and thymus cellularity;
mitogen-stimulated cell proliferation; KLH-stimulated primary and
secondary serum IgG and IgM titres; and KLH-stimulated lym-
phoproliferation and cytokine release in cultured splenic lympho-
cytes following ex vivo exposure to the antigen. Antigen challenge
and response was variously conducted at around four, eight, or ten
weeks of age. In most cases, IgMwas not elevated by treatment, and
while the relative sensitivity of other endpoints varied they were
generally of a similar order of magnitude. Of note, the sensitivity of
lymphoid organ weights and spleen cellularity, which along with
IgM are the only parameters that were investigated that are also
required as part of the EOGRTS (OECD, 2011a), did not differ greatly
to that of IgG, KLH-mediated proliferation, and cytokine release. IgG
and cytokine release may be incorporated into follow-up in-
vestigations to the EOGRTS if necessary (Boverhof et al., 2014;
OECD, 2013).
While there are differences in the sensitivity of the immature
and mature immune systems to toxic insultdparticularly with
respect to persistencedand some functional parameters may be
more sensitive than other endpoints, the available evidence from
adult mouse models suggests that a combined evaluation of
lymphoid organ weights, histopathology, cellularity, and haema-
tology is at least equally sensitive to plaque-forming cell respon-
sesdthe additional evaluation performed in cohort 3dfor
detecting immunotoxicity (Table 2). If cohort 3 is not triggered due
to lack of such ﬁndings in previous studies, but then effects on
lymphoid organs, cellularity or haematology are identiﬁed in the
EOGRTS F1 adults, they would trigger further evaluation in a
separate DIT study. Further information on the responsiveness of
the endpoints that are routinely evaluated in repeated dose toxicity
studies and the EOGRTS may be helpful in clarifying the sensitivity
of the available triggers.
Oestrogens play a role in the development and control of im-
mune function (Cunningham and Gilkeson, 2011; Soucy et al.,
Table 2
Sensitivity and speciﬁcity of immunotoxicity endpoints. An analysis of the sensitivity, speciﬁcity, and concordance of endpoints that are evaluated in repeated dose toxicity
studies with immunotoxicity classiﬁcation for 51 substances tested in adult female B6C3F1 or C57BL/6 mice. Immunotoxicity classiﬁcation was assigned on the basis of
performance in speciﬁc functional assays (Luster et al., 1992).
Endpoint or combination of endpoints affected by treatment Number of chemicals Sensitivity Speciﬁcity Concordance
Organ endpoints
Thymus weight relative to body weight 40 0.54 1.00 0.68
Spleen weight relative to body weight 41 0.52 0.83 0.61
Spleen cellularity 36 0.38 0.92 0.56
Haematology
Leukocytes 30 0.20 0.90 0.43
Combination effects
Thymus and spleen weights relative to body weight 40 0.36 1.00 0.55
At least one organ endpoint 45 0.77 0.80 0.78
Any two of three organ endpoints 40 0.46 1.00 0.63
All three organ endpoints 32 0.13 1.00 0.38
At least one organ endpoint or leukocytes 46 0.81 0.73 0.78
Functional observations
Plaque-forming cell (PFC) response 45 0.66 1.00 0.78
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oestrogen agonists and antagonists (Kalland et al., 1979; Luebke
et al., 2006). Consequently, evidence of endocrine disrupting ac-
tivity in vivo, especially oestrogenic or anti-oestrogenic, might be a
cause for further evaluation.
In repeated dose studiesdparticularly those required for regu-
latory purposes and performed according to OECD guide-
linesdblood samples are taken before necropsy; total and
differential leucocyte counts might provide indications of an
immunotoxicological mode of action. At necropsy, the spleen and
thymus are weighed, ﬁxed, and examined for histopathological
changes. Histopathological examinations are also done for
mesenteric and axillary lymph nodes, Peyer’s patches and bone
marrow.
Indicators of immunosuppression in standard rat toxicity
studies (OECD, 1996, 1998, 2002a, 2008b, 2009a, 2015a) include
haematology, clinical chemistry, and anatomical pathology. Rele-
vant haematological endpoints are leukopenia, if not associated
with severe body weight decrease, severe kidney damage, or multi-
morbid status; neutropenia, if not associated with anaemia, severe
kidney damage, liver cirrhosis, or hypothyroidism; lymphopenia, if
not associated with acute inﬂammation, damage to lymph nodes,
chronic renal failure, severe stress, hyperadrenocorticism, or severe
heart failure; and eosinopenia, if not associated with stress,
hyperadrenocorticism, or acute inﬂammation. The determination
of hypoglobulinaemia as part of the clinical chemistry battery may
indicate immunosuppression if noted in the absence of other cau-
ses such as severe liver or kidney damage, haemorrhagic or hae-
molytic anaemia, over-hydration, or dysproteinaemia affecting
transport globulins. The non-immunosuppressive causes for alter-
ations in these haematological and clinical chemistry parameters
can be excluded by changed standard clinical pathology parameters
like liver enzymes, urea, creatinine, red blood cell parameters and
by histopathology investigations.
Decreased organ weights of thymus, spleen, lymph nodes in
combination with histopathology ﬁndings, like atrophy and cell
depletion in spleen, thymus, lymph node, and bone marrow at
lower doses than those eliciting systemic toxicity may be an indi-
cator of immunotoxicity. Isolated weight alterations of the
mentioned organs without histopathology ﬁndings are rather more
an expression of systemic toxicity than immunotoxicity. Atrophy of
the thymus in subchronic studies but not in chronic studies may be
an indicator of immunotoxicity (Kuper et al., 2000; US EPA, 2013).
4.3.1. Differentiation of immunosuppression versus stress
It is crucial to differentiate between a primaryimmunosuppressive effect and subacute stress in repeated dose
studies. A primary immunosuppression may be suspected if the
effects in lymphoid organs (atrophy, hypocellularity, leukopenia
etc.) are found in the absence of other adverse effects. Stress as a
cause of the alterations in immune system parameters may be
conﬁrmed if the effects tend not to be dose-dependent and if
occurring concomitantly with either decreased food consumption
and body weight, decreased thymus weight in the absence any
other altered lymphoid organs, hypertrophy of the zona fasciculata
of the adrenal cortex, or neutrophilia combined with eosinopenia
(Everds et al., 2013).
4.3.2. Additional immunotoxicity parameters in standard toxicity
studies
If QSAR analysis, toxicokinetic data, or previous study results
reveal a potential for an immunosuppressive potential of the
compound, additional parameters can be included in the subse-
quent regulatory studies (e.g. subchronic repeated dose toxicity
study) without increasing the animal numbers. Regarding clinical
pathology, the following parameters can be included in rodent
studies: serum electrophoresis, to differentiate between a deﬁ-
ciency of transport globulins and immunoglobulins; immuno-
globulins, direct immunologic measurement of immunoglobulin
fractions in serum (IgG, IgM, eventually IgA and IgE); and cytokines.
The direct measurement of blood cytokine levels is a poor indicator
of functional suppression of the immune system, because normal
serum levels are very low and a decrease cannot be measured
(House, 1999). However, if there is an indication of, or concern for,
immunosuppression, blood and/or spleen cells isolated from rats in
repeated dose studies can be used to measure cytokine production
(Ai et al., 2013, 2014; Barten et al., 2006). For comparison reasons a
standard protocol for these ex vivo assays will be necessary (Dietert
and Holsapple, 2007).
While skin sensitisation data may be available prior to an
EOGRTS, it is unlikely to be useful informing a decision to trigger
cohort 3. The TDAR assays required as part of OECD 443 detect
immune suppression, but not immune responses directed toward
chemicals. There are many agents that can affect TDAR assays, and
there is no single Adverse Outcome Pathway that encompasses all
of them. In contrast, skin sensitisation assays assess the potential
for the adaptive immune system to recognise and attack
chemically-modiﬁed proteins. There is a single OECD-accepted
Adverse Outcome Pathway describing how the process unfolds
for a multitude of chemicals (OECD, 2014). In essence, a ﬁnding of
sensitisation is a ﬁnding that a memory immune response directed
toward chemically-modiﬁed proteins can develop. However, this
N.P. Moore et al. / Regulatory Toxicology and Pharmacology 80 (2016) 32e40 39does not alter the ability to generate memory responses toward
other targets of immunity (e.g., bacteria, viruses, or tumours).
Development of a memory response directed toward a speciﬁc
chemically-modiﬁed protein, the domain of skin sensitisation as-
says, generally has little implication on the global function of the
adaptive immune system, the domain of TDAR. A change in one has
no anticipated biological relationship to the other, and conse-
quently evidence of skin sensitisation should not be construed as a
trigger for cohort 3.
5. Additional triggers
Further to the triggers that have been suggested herein, addi-
tional triggers may be stipulated within speciﬁc regulatory frame-
works. These may reﬂect regulatory policy towards wider
registration requirements and an overall testing strategy, and may
not be strictly related to the biological relationships described
above. The practitioner is guided to consult the speciﬁc regulatory
requirements in such cases.
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